PHASE I EVALUATION OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE CSF

集落刺激因子是一组细胞因子，具有 增强骨髓产生的理想特性 粒细胞和巨噬细胞。 这些细胞因子可能对 肿瘤学家的兴趣，如果他们能够增加外周 血粒细胞计数无显著相关毒性， 接受骨髓抑制治疗的患者。 本研究是一项 重组人GM-CSF的I期评价。 患者 具有合理完整骨髓的实体瘤将接受 逐步增加GM-CSF的剂量，试图确定 最大耐受剂量和显著 外周血粒细胞计数和粒细胞 可以观察到单核细胞功能。 迄今为止，只有1名患者入选本试验， 还可以对毒性或抗肿瘤性进行评论， 有效性

Colony stimulating factors are a group of cytokines that have the desirable property of enhancing marrow production of granulocytes and macrophages. These cytokines might be of great interest to oncologists if they are capable of increasing peripheral blood granulocyte counts without significant associated toxicity in patients receiving myelosuppressive therapy. This study is a phase I evaluation of recombinant human GM-CSF. Patients with solid tumors with reasonably intact bone marrows will receive escalating doses of GM-CSF in an attempt to determine the maximally tolerated dose and the dose at which significant increases in peripheral blood granulocyte counts and granulocyte and monocyte function can be observed. Only 1 patient has been admitted to this trial to date, and no comment can yet be made as to toxicity or antitumor effectiveness.